| Name | Title | Contact Details |
|---|
ODONA/LTC is a Shaker Hts, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HOYA Vision Care Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. Our products reach millions of people every day, as we fight to improve global access to the highest quality hygiene, wellness and nourishment. We`re a growing community of 40,000+ diverse, talented entrepreneurs, and the driving force behind some of the world`s most loved and trusted brands. Our portfolio includes household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Lysol, Dettol, Harpic, Cillit Bang, Finish and Vanish. Hygiene, Health and Nutrition are the focus areas of our business, and the categories under which our brands are organised. Each area is dedicated to building sustainable solutions that will help us address the challenges presented by global mega-trends like urbanisation, climate change and digital transformation. These global pressures are challenging public health systems and increasing the need for improved hygiene products, services and education. We continuously innovate in areas like personalised nutrition, wellness, and digital health and hygiene so that individuals, families and communities can live cleaner, healthier lives.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
IntraMed Educational Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.